Abivax SA (ABVX)
114.59
-0.90
(-0.78%)
USD |
NASDAQ |
Jan 09, 16:00
115.55
+0.96
(+0.84%)
After-Hours: 18:35
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 8.989B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 1.63K% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France. |
| URL | http://www.abivax.com |
| Investor Relations URL | https://ir.abivax.com/ |
| HQ State/Province | Ile-de-France |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 23, 2026 |
| Last Earnings Release | Sep. 08, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France. |
| URL | http://www.abivax.com |
| Investor Relations URL | https://ir.abivax.com/ |
| HQ State/Province | Ile-de-France |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 23, 2026 |
| Last Earnings Release | Sep. 08, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |